|Day's Range||35.08 - 35.09|
|52 Week Range||33.52 - 38.86|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.63%|
PharmaMar (PHM) has announced today a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in Turkey. Under the terms of the agreement, PharmaMar will receive an upfront payment as well as development milestones related to the health approval procedure of Aplidin® in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacıbaşı for commercial use.
MADRID, May 19, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis ® and lurbinectedin, during the 53 ...
Some 20 years ago, a low rumbling of change began to build in the retail industry. Remember when Amazon, despite losing billions of dollars a year, started to eat the market-share lunch of bookstores? There was clear disruption going on, but really in a small material way back then. However, there were those who saw the future, and extrapolated that what Amazon was doing to bookstores would happen across retail. Many scoffed.